Our website use cookies to improve and personalize your experience and to display advertisements (if any). Our website may also include cookies from third parties like Google Adsense, Google Analytics, and Youtube. By using the website, you consent to the use of cookies.

‘Nigeria isn’t ready to deal with rising cases’

‘Nigeria isn’t ready to deal with rising cases’

WITH rising cases of the Delta variant of the SARS-CoV-2 virus in Nigeria, there is heightened concern about how well the country is prepared to deal with them. The Conversation Africa’s Wale Fatade asked public health expert Doyin Odubanjo what Nigeria should do. DOYIN ODUBANJO, Executive Secretary, Nigerian Academy of Science What makes the Delta variant different from other COVID-19 variants? The variant has now become the main one of concern globally and is believed to be the cause of the recent surge in cases seen in Asia and Africa. It is also believed to be behind the rise in…
Read More
Russian vaccine can deal with mutations

Russian vaccine can deal with mutations

A Russian trial testing the effectiveness of revaccination with the Sputnik V shot to protect against new mutations of the coronavirus is producing strong results, researchers have said. Last month President Vladimir Putin ordered a review by March 15 of Russian-produced vaccines for their effectiveness against new variants spreading in different parts of the world. "(A) recent study carried out by the Gamaleya Centre in Russia showed that revaccination with Sputnik V vaccine is working very well against new coronavirus mutations, including the UK and South African strains of coronavirus," said Denis Logunov, a deputy director of the centre, which…
Read More
Vaccine shows 51% efficacy against variant

Vaccine shows 51% efficacy against variant

JULIE STEENHUYSEN NOVAVAX Inc's COVID-19 vaccine had efficacy of 51% against infections caused by the South African variant among people who were HIV negative, and 43% in a group that included people who were HIV positive, according to a new analysis published on Wednesday. The variant, known as B.1.351, carries mutations that threaten the efficacy of COVID-19 vaccines, several studies have shown. Most vaccine makers, including Novavax, are testing versions of their vaccines to protect against emerging variants. The Novavax post-hoc analysis was published in the New England Journal of Medicine along with full data from the company's trial in…
Read More